Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4

Collins, Paul J., McCully, Michelle L., Martínez-Muñoz, Laura, Santiago, César, Wheeldon, James, Caucheteux, Stephan, Thelen, Sylvia, Cecchinato, Valentina, Laufer, Julia M., Purvanov, Vladimir, Monneau, Yoan R., Lortat-Jacob, Hugues, Legler, Daniel F., Uguccioni, Mariagrazia, Thelen, Marcus, Piguet, Vincent, Mellado, Mario and Moser, Bernhard 2017. Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB Journal 31 (7) , pp. 3084-3097. 10.1096/fj.201700013R

[thumbnail of FASEB J-2017-Collins-3084-97.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


The chemokine receptor, CXC chemokine receptor 4 (CXCR4), is selective for CXC chemokine ligand 12 (CXCL12), is broadly expressed in blood and tissue cells, and is essential during embryogenesis and hematopoiesis. CXCL14 is a homeostatic chemokine with unknown receptor selectivity and preferential expression in peripheral tissues. Here, we demonstrate that CXCL14 synergized with CXCL12 in the induction of chemokine responses in primary human lymphoid cells and cell lines that express CXCR4. Combining subactive concentrations of CXCL12 with 100–300 nM CXCL14 resulted in chemotaxis responses that exceeded maximal responses that were obtained with CXCL12 alone. CXCL14 did not activate CXCR4-expressing cells (i.e., failed to trigger chemotaxis and Ca2+ mobilization, as well as signaling via ERK1/2 and the small GTPase Rac1); however, CXCL14 bound to CXCR4 with high affinity, induced redistribution of cell-surface CXCR4, and enhanced HIV-1 infection by >3-fold. We postulate that CXCL14 is a positive allosteric modulator of CXCR4 that enhances the potency of CXCR4 ligands. Our findings provide new insights that will inform the development of novel therapeutics that target CXCR4 in a range of diseases, including cancer, autoimmunity, and HIV.—Collins, P. J., McCully, M. L., Mart´ınez-Muñoz, L., Santiago, C.,Wheeldon, J., Caucheteux, S., Thelen, S., Cecchinato, V., Laufer, J.M., Purvanov, V.,Monneau, Y. R., Lortat-Jacob, H., Legler, D. F., Uguccioni, M., Thelen, M., Piguet, V., Mellado, M., Moser, B. Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB J. 31, 000–000 (2017).

Item Type: Article
Date Type: Publication
Status: Published
Schools: Advanced Research Computing @ Cardiff (ARCCA)
Additional Information: This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0)
Publisher: Federation of American Society of Experimental Biology (FASEB)
ISSN: 0892-6638
Funders: The Welcome Trust, MRC
Date of First Compliant Deposit: 6 June 2017
Date of Acceptance: 13 March 2017
Last Modified: 21 Aug 2022 08:29

Citation Data

Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics